Menu
Search
|

Menu

Close
X

Inflarx NV IFRX.OQ (NASDAQ Stock Exchange Global Select Market)

3.01 USD
-0.07 (-2.27%)
As of 12:27 PM EDT
Previous Close 3.08
Open 3.08
Volume 17,417
3m Avg Volume 285,521
Today’s High 3.08
Today’s Low 2.98
52 Week High 52.41
52 Week Low 2.45
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.25 Mean rating from 8 analysts

KEY STATS

Revenue (mm, EUR)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (EUR)
FY19
-0.967
FY18
-1.173
FY17
-1.003
FY16
-0.520
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
--
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Winzerlaer Str. 2
JENA     07745

Phone: +493641.508180

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

SPONSORED STORIES